Research and development spending to bring a single cancer drug to market and revenues after approval

JAMA Internal Medicine

Volumn 177, Issue 11, 2017, Pages 1569-1575

  Prasad, Vinay ^a,b   Mailankody, Sham ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; PROFIT; UNITED STATES; COST; ECONOMICS; FINANCIAL MANAGEMENT; HUMAN;

ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; DRUG APPROVAL; DRUG COSTS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 85033549033     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.3601     Document Type: Article

References (27)

1. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539-540.
2. Wertheimer A, Bush P. Ask the pharmacists: sticker shock at the pharmacy counter. phillycom. 2017. http://www.philly.com/philly/health/Ask-the -pharmacists-Sticker-shock-at-the-pharmacy-counter.html. Accessed July 31, 2017.
3. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6): 381-390.
4. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-4442.
5. Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996-1000.
6. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016; 47:20-33.
7. Avorn J. The $2.6 billion pill–methodologic and policy considerations. N Engl J Med. 2015;372(20): 1877-1879.
8. Young B, Surrusco M. Rx R&D Myths: The Case Against the Drug Industry’s R&D“Scare Card.” Washington, DC: Public Citizen’s Congress Watch; 2001. https://www.citizen.org/sites/default/files/rdmyths.pdf. Accessed July 31, 2017.
9. US Securities and Exchange Commission. Form 10-K. Washington, DC: US Securities & Exchange Commission; June 26, 2009.
10. Buffett EC. Expect 6%-7% returns from the market. The Street. https://www.thestreet.com /story/10084972/1/buffett-expect-6-7-returns -from-the-market.html. Accessed July 31, 2017.
11. Gassman AL, Nguyen CP, Joffe HV. FDA regulation of prescription drugs. N Engl J Med. 2017; 376(7):674-682.
12. Herper M. The truly staggering cost of inventing new drugs. Forbes. https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering -cost-of-inventing-new-drugs/#5f0fb73d4a94. Published February 10, 2012. Accessed July 31, 2017.
13. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214.
14. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008; 5(1):e1.
15. Sox HC, Rennie D. Seeding trials: just say “no”. Ann Intern Med. 2008;149(4):279-280.
16. DiMasi J, Grabowski H. The cost of biopharmaceutical R&D: is biotech different? Manage Decis Econ. 2007;28(4-5):469-479. doi:10 .1002/mde.1360
17. Dranove D, Meltzer D. Do important drugs reach the market sooner? Rand J Econ. 1994;25(3): 402-423.
18. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992-1994.
19. Wang B, Liu J, Kesselheim AS. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern Med. 2015;175(4):635-637.
20. Yu N, Helms Z, Bach P. R&D costs for pharmaceutical companies do not explain elevated US drug prices. Health Affairs Blog. http: //healthaffairs.org/blog/2017/03/07/rd-costs -for-pharmaceutical-companies-do-not-explain -elevated-us-drug-prices/. Published March 7, 2017. Accessed July 31, 2017.
21. Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA. 2014;311(4):353-354.
22. Hagen T. Ponatinib (CML) pricing gets a blast from Congress. OncLive. http://www.onclive.com/web-exclusives/ponatinib-cml-pricing-gets-a -blast-from-congress. Published October 21, 2016. Accessed July 31, 2017.
23. Derrick J. Bernie Sanders and Rep. Cummings to Ariad: explain why Iclusig now costs $199,000 a year. Benzinga. https://www.benzinga.com /general/biotech/16/10/8584112/bernie-sanders -and-rep-cummings-to-ariad-explain-why-iclusig -now-costs. Published October 20, 2016. Accessed July 31, 2017.
24. Nordrum A. Drug prices: world’s most expensive medicine costs $440,000 a year: but is it worth the expense? http://www.ibtimes.com/drug-prices-worlds-most-expensive-medicine-costs -440000-year-it-worth-expense-2302609. Published February 13, 2016. Accessed July 31, 2017.
25. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31(4):412-419.
26. Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005-3013.
27. Lee S. Exelixis to lay off 70 percent of staff after prostate cancer drug bombs. SFGate. http://blog.sfgate.com/techchron/2014/09/02/exelixis -to-lay-off-70-percent-of-staff-after -prostate-cancer-drug-bombs/. Published September 2, 2014. Accessed July 31, 2017.